STCube "Follow-up Meetings Confirmed for Technology Transfer at Bio USA"

[Asia Economy Reporter Hyungsoo Park] Immuno-oncology company STCube announced on the 24th that it successfully completed discussions for technology licensing with global big pharma companies by participating in the ‘2022 BIO International Convention (BIO USA).’

STCube held partnering meetings with a total of over 20 global pharmaceutical companies, including 10 companies that requested pre-meetings such as Pfizer and BMS, as well as Amgen, AbbVie, Roche, Boehringer Ingelheim, and Sanofi.

An STCube representative said, "We were able to confirm the high level of interest from global pharmaceutical companies regarding the clinical data of ‘hSTC810,’ which is being developed as an innovative new drug." He added, "We received numerous inquiries and various questions about the clinical status. Among them, we received proposals from multiple global big pharma companies and have scheduled follow-up meetings."

STCube is currently conducting global and domestic Phase 1 clinical trials of the immune checkpoint inhibitor new drug candidate hSTC810. Based on the excellent preclinical results of hSTC810, the company has set a goal to successfully achieve both clinical trials and technology licensing this year.

hSTC810 is a new drug candidate discovered by STCube that targets the immune checkpoint protein ‘BTN1A1.’ The hSTC810 antibody binds to BTN1A1 and blocks the interaction between BTN1A1 and its ligand. It has a mechanism of action that activates immune cells to eliminate cancer cells.

This content was produced with the assistance of AI translation services.